Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.71 | N/A | +40.87% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.71 | N/A | +40.87% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding their product pipeline. However, they did not provide specific guidance for future quarters.
Management highlighted strong performance in key therapeutic areas.
They expressed confidence in ongoing clinical trials and pipeline development.
Bristol Myers Squibb's earnings report showed a strong EPS beat, indicating better-than-expected profitability. However, the stock fell by 0.95%, possibly due to the lack of revenue data and forward guidance. Investors may be cautious as the company navigates its pipeline and market conditions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WASTE CONNECTIONS IN
Apr 27, 2015